SCHEMBL3271368

SCHEMBL3271368

O=[N+]([O-])c1ccccc1NCC1(c2ccc(OCCCN3CCCC3)cc2)CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 10/20 0.51
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
LTA4H P09960 2/20 0.48
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KCNH2 Q12809 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CACNA1B Q00975 1/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3277514 0.88 HRH3 (0.48) HRH3CYP1A2CYP2D6CYP2C19LTA4H
SCHEMBL5313460 0.88 CYP1A2 (0.48) HRH3CYP1A2CYP2D6CYP2C19LTA4H
SCHEMBL3277211 0.87 LTA4H (0.50) HRH3CYP1A2CYP2D6CYP2C19LTA4H
SCHEMBL3271349 0.84 HRH3 (0.55) HRH3LTA4HKCNH2ALDH1A1CACNA1B
SCHEMBL3272766 0.79 HRH3 (0.58) HRH3CYP1A2KCNH2ALDH1A1HRH2
SCHEMBL3271377 0.79 HRH3 (0.55) HRH3LTA4HPTGS2KCNH2HRH2
SCHEMBL3271840 0.78 HRH3 (0.57) HRH3KCNH2HRH2HRH1
SCHEMBL3272777 0.77 HRH3 (0.64) HRH3CYP1A2KCNH2ALDH1A1
SCHEMBL3272881 0.76 HRH3 (0.54) HRH3CYP1A2LTA4HKCNH2ALDH1A1
SCHEMBL3273298 0.76 HRH3 (0.52) HRH3CYP1A2CYP2D6CYP2C19LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747210-B1 3- OR 4-MONOSUBSTITUTED PHENOL AND THIOPHENOL DERIVATIVES USEFUL AS H3 LIGANDS WARNER LAMBERT CO (US) 2010-06-30 EP disclosed
US-7456164-B2 Useful for treatment of H3-related diseases such as neurologic disorders, or inflammatory, respiratory and allergic diseases, disorders and conditions; for example, 4-[4-(1-isopropylpiperidin-4-yloxy)phenyl]tetrahydropyran-4-carbonitrile; well absorbed from gastrointestinal tract, metabolically stable PFIZER, INC (US) 2008-11-25 US disclosed
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands ZIARCO INC. 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267095-A1 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands HRH4, HRH3, TLR4 HRH3 2/4885CYP1A2 319/4885CYP2D6 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.